Cargando…
Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment
Through a unique genomics and drug screening platform with ~800 solid tumor cell lines, we have found a subset of SCLC cell lines are hypersensitive to venetoclax, an FDA-approved inhibitor of BCL-2. SCLC-A (ASCL1 positive) and SCLC-P (POU2F3 positive), which make up almost 80% of SCLC, frequently e...
Autores principales: | Neely, Victoria, Manchikalapudi, Alekhya, Nguyen, Khanh, Dalton, Krista, Hu, Bin, Koblinski, Jennifer E., Faber, Anthony C., Deb, Sumitra, Harada, Hisashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487506/ https://www.ncbi.nlm.nih.gov/pubmed/37685889 http://dx.doi.org/10.3390/ijms241713082 |
Ejemplares similares
-
The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3
por: Vaughan, Catherine A., et al.
Publicado: (2021) -
Gain‐of‐function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells
por: Vaughan, Catherine A., et al.
Publicado: (2017) -
Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites
por: Vaughan, Catherine A., et al.
Publicado: (2014) -
Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015) -
Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)